ISSN: 2754-4737

Journal of Neurology Research Reviews & Reports

SCIENTIFIC Research and Community

Research Article

Open Access

Quantitative EEG Evidence of Cognitive Restoration in Alzheimer's Disease Following Biophoton Generator Therapy

James Z Liu[1,2*], Mariola A Smotrys[1,2], Seth D Robinson[2], Hui X Yu[2], Sherry X Liu[2], Devin R Liu[2], and Helen Y Gu[1,2]

[1]First Institute of All Medicines, 139 Pittsburg Road, Butler, PA 16001, USA

[2]Tesla BioHealing, Inc. 111 McCoy Street, Milford, DE 19963, USA

ABSTRACT

Background: Alzheimer's disease (AD) is marked by progressive cognitive and electrophysiological decline. Existing treatments offer limited symptomatic relief without reversing underlying pathology. Recent advances in biophoton therapy offer a novel, non-invasive strategy targeting mitochondrial and neural function.

Objective: To evaluate the neurophysiological and cognitive effects of biophoton generator therapy in AD patients using quantitative EEG (qEEG) metrics.

Methods: A randomized, triple-blinded, placebo-controlled clinical trial was conducted in 24 AD patients but 4 with serial EEG recordings were analyzed and reported in this article. Participants received nightly exposure to four strong biophoton generators for 2 to 4 weeks. Key EEG biomarkers assessed included posterior peak alpha frequency, theta/beta ratio, frontal alpha asymmetry, and P300 event-related potentials.

Results: Placebo-phase data showed negligible EEG changes. In contrast, 2 to 4 weeks of active treatment led to increased alpha and beta power, reduced delta/theta activity, improved interhemispheric coherence, elevated EEG entropy, and enhanced P300 amplitude with shorter latency. Improvements were consistent across spectral, topographic, and ERP domains, suggesting cognitive restoration and neural plasticity.

Conclusion: Strong biophoton generator therapy significantly improved qEEG biomarkers in AD patients within a short treatment window. These findings support further investigation into biophoton therapy as a safe, scalable intervention for neurodegenerative disorders.

***Corresponding author**

James Z Liu, MD, PhD, President, First Institute of All Medicines, 1000 Uniqema Blvd, New Castle, DE 19720, USA.

Received: July 07, 2025; **Accepted:** July 15, 2025; **Published:** July 22, 2025

Keywords: Alzheimer's Disease, Biophoton Therapy, Quantitative EEG, Neural Coherence, P300, Neuroplasticity, Electrophysiology

Introduction

Alzheimer's disease (AD) poses one of the most significant public health challenges of the 21st century. As the most prevalent form of dementia, it currently affects over 55 million people worldwide, with this number projected to reach 140 million by 2050, due to global population aging [1,2]. The disease is marked by a progressive decline in memory, cognition, and functional independence, leading to immense personal, familial, and societal burdens. In 2023 alone, the global cost of dementia-related care exceeded $1.3 trillion [3].

Despite decades of research, current treatment options for AD remain limited. Conventional pharmacological therapies, such as cholinesterase inhibitors and NMDA receptor antagonists, offer only temporary symptomatic relief and do not address the underlying causes of neurodegeneration [3]. Recent approaches targeting amyloid-β and tau protein pathologies have produced limited benefits and raised safety concerns [3-5]. Moreover, growing evidence suggests that mitochondrial dysfunction, oxidative stress, neuroinflammation, and bioenergetic failure play foundational roles in AD progression highlighting the need for more comprehensive, non-invasive, and cellular-level therapeutic strategies [6-9].

One such promising approach is the application of strong biophoton generators. Biophotons are ultra-weak, coherent light emissions naturally produced by living cells and closely tied to mitochondrial activity, redox signaling, and intercellular communication [9-13]. Strong biophoton generators amplify these natural emissions to therapeutic levels, aiming to restore mitochondrial bioenergetics, reduce neuroinflammation, enhance cerebral microcirculation, and improve cognitive function.

Preliminary clinical studies and quantitative EEG (qEEG) analyses have shown that Alzheimer's patients treated with strong biophoton generators demonstrated significant improvements in attention, memory, mood regulation, and cognitive performance within weeks. These outcomes are supported by objective EEG biomarkers, including increased posterior peak alpha frequency, normalized theta/beta ratios, improved frontal alpha asymmetry, and enhanced P300 waveforms indicators of attention, working memory, and neural processing speed [14]. The preliminary outcome of using strong biophoton generators to successfully treat

Alzheimer's disease was reported by our group in the Alzheimer's Association International Conference (AAIC) in 2024 [15]. This integrative, non-invasive intervention offers a multi-targeted mechanism aligned with the complex pathophysiology of AD and holds promise as a transformative solution in the global fight against Alzheimer's disease. This article is to report on the impact of biophoton generators on EEG biomarkers.

Materials and Methods

Study Design. The overall clinical study was a randomized, triple blinded and placebo-controlled clinical trial and registered at clinicaltrials.gov (ID: NCT06147999). The four cases who had high resolution EEG reports were selected to assess the cognitive and neurophysiological effects of strong biophoton generators in individuals diagnosed with mild to moderate Alzheimer's disease (AD) over a 4-week treatment period. Ethics and Regulatory Compliance: the clinical study was approved by an independent Institutional Review Board (IRB). Informed consent obtained in accordance with the Declaration of Helsinki.

Investigational product and mode of administration. Tesla BioHealing® biophoton generators were over-the-counter (OTC) medical device and it could be used by anyone who wants to increase blood circulation and reduce bodily pains, according to the label claims. Four biophoton generators were placed under the hotel bed and the study participant was sleeping on the bed during the study period. The participant's caregiver recorded the cognition and brain function changes and answered the standard study questionnaires at the baseline, and weekly during the 4-week study period.

Participants met all inclusion criteria: (1) Male or female 50 - 85 years of age; (5) had evidence of a clinical diagnosis of AD prior to study participation; (3) signed informed consent or signed by the caregiver; (4) could live in a wellness hotel during the entire study period; (5) had a caregiver willing to support the participant's full involvement in the study and could assist to complete all study questionnaires.

Participants also met all exclusion criteria: (6) untreated psychiatric disturbances that would affect trial participation as judged by the Caregiver or by the clinical study medical professional, (7) who relies on ventilators; (8) co-morbid conditions that would interfere with study activities or response to treatment, which may include severe chronic pulmonary disease, history of uncontrolled seizures, acute or chronic infectious illness, kidney failure, etc.; (9) history of moderate or more severe traumatic brain injury in the 2-years prior to signing the consent to participate in the study; (10) was participating in another investigational drug or device trial; (11) was unable or unwilling to comply with protocol follow-up requirements; (12) had an active infectious disease, such as COVID-19.

Outcome Measurement was the change in quantitative EEG (qEEG) biomarkers: (1) Posterior Peak Alpha Frequency (cognitive processing); (2) Theta/Beta Ratio (attention/inattention); (3) Frontal Alpha Asymmetry (mood); (4) P300 latency and amplitude (attention and memory ERP marker) [14].

BrainView supplied by Medeia is a quantitative electroencephalogram (EEG) and used during this clinical study. The BrainView system is an FDA-cleared, state-of-the-art hardware and software platform designed for comprehensive and objective brain assessments. By utilizing EEG activity, Event-Related Potentials (ERP) processing speeds, and neuropsychological testing, BrainView aid physicians and investigators with the tools needed for accurate and timely diagnoses. By capturing and analyzing brainwave activity, auditory and visual evoked potentials, and physiological stress responses, BrainView provides a comprehensive snapshot of neurocognitive function in under 30 minutes (https://www.brainview.com). The resulting data is compared to a large normative database to help identify abnormalities associated with conditions such as Alzheimer's disease, mild cognitive impairment (MCI), traumatic brain injury (TBI), depression, anxiety, PTSD, ADHD, and more, according to the information provided by the manufacturer. BrainView is a valuable asset in both academic research and routine care, helping to bridge the gap between subjective symptoms and measurable brain function.

Results

Case 1 Presentation - EEG Evidence from the Placebo and Treatment

Subject AD-126 was an 85-year-old female with moderate Alzheimer's disease. She was randomized to the Control Group and for the first two weeks, she had slept on the bed powered with 4 Placebo devices. Then she was switched to the Active Treatment after the 2-week placebo-phase. Based on a detailed comparison of the baseline and week 2 placebo EEG reports of Alzheimer's patient AD126, the findings confirm that there are no clinically meaningful improvements following 2 weeks of placebo treatment. The subject's Cognitive and EEG Frequency Metrics were provided in Table 1.

Table 1: Cognitive and EEG Frequency Metrics during the Placebo Phase

Metric	Baseline	Week 2 Placebo	Reference Range	Interpretation
Posterior Peak Frequency (Eyes Closed)	7.8 Hz	8.2 Hz	8–12 Hz	Slight rise, still suboptimal
Posterior Peak Frequency (Eyes Open)	8.7 Hz	8.3 Hz	8–12 Hz	Small decline
Theta/Beta Ratio (Eyes Open)	0.85	0.83	< 1	Both within normal
Frontal Alpha Asymmetry	-10%	-3%	-10% to 10%	Improved slightly
Alpha Ratio (Closed/Open)	1.84	1.75	> 1.2	Slight drop

The EEG measures showed slight fluctuations but no trend indicating therapeutic improvement. Variations were within the natural variability range for elderly individuals with Alzheimer's disease.

The subject's functional deviations (Z-Score Brain Maps) during the placebo phase were compared to the Baseline, which was shown in Figure 1.



Figure 1: Brain Map source at the Baseline and during the Placebo Phase

The above indicated that the same affected regions, similar Z-score magnitudes, and there was no evidence of neurophysiological improvement.

In Summary: The EEG profiles at baseline and after 2 weeks of placebo treatment are remarkably similar, with (1) no improvement in posterior peak frequency; (2) persistent abnormalities in prefrontal and temporal regions; (3) Z-scores that remain outside normal limits, especially in memory, attention, and language-related areas. This stability over 2 weeks confirms that placebo had no therapeutic effect on EEG brain metrics in this Alzheimer's patient.

After the study participant was switched to the active treatment phase for 2 and 4 weeks, her EEG measurements at Week 4, and Week 6 were improved from the Baseline and Placebo phase, as indicated in Tables 2 to 5.

Table 2: Posterior Peak Frequency (Cognitive Processing Capacity)

Condition	Eyes Closed	Eyes Open
Baseline	7.8 Hz (↓)	8.7 Hz
Week 2 (Placebo)	8.2 Hz	8.3 Hz
Week 4 (Active Treatment)	9.5 Hz (↑)	8.9 Hz (↑)
Week 6 (Active Treatment)	9.2 Hz	8.9 Hz

Interpretation: Peak frequency rose most in Week 4, indicating improved semantic memory and information processing. Week 6 maintained the higher cognitive baseline, showing stability and post-treatment compared to Control.

Table 3: Theta/Beta Ratio (Marker of Inattention)

Condition	Ratio (Eyes Open)	Interpretation
Baseline	0.85	Slightly elevated (suboptimal)
Week 2	0.83	Stable from Baseline
Week 4	0.82	No change
Week 6	0.70	Improved attention

Interpretation: the attention improved by Week 6 relative to baseline, 4 weeks after the active treatment.

Table 4: Frontal Alpha Asymmetry (Mood Indicators)

Condition	Frontal Alpha Asymmetry	Interpretation
Baseline	-10%	Edge of depression range
Week 2	-3%	Significantly improved mood
Week 4	-2%	Maintained positive shift
Week 6	-2%	Within normal

Interpretation: Significant mood and anxiety improvement observed after 2 weeks, which could have a placebo effect, but the improvement remained 4 and 6 weeks after the active treatment.

Table 5: Eyes Closed / Open Alpha Ratio (Vigilance Regulation)

Condition	Alpha Ratio	Interpretation
Baseline	1.84	Elevated; possible drowsiness or impaired vigilance
Week 2	1.75	Slight normalization
Week 4	1.65	Continued improvement
Week 6	1.46	Approaching normal range

Interpretation: Steady improvement in vigilance and arousal regulation with biophoton exposure.

Table 6: ERP and Behavioral Reaction Metrics

Measure	Week 4	Week 6	Norm
Visual Reaction (N2)	292 ms (↑)	276 ms (↑)	< 220 ms
Attention (P3)	356 ms	332 ms	< 340 ms
Working Memory (N4)	444 ms	452 ms	< 480 ms
Reaction Time	463 ms	488 ms	350–500 ms
Wrong Responses	1.5%	0.7%	≤ 4%

Interpretation: Improved accuracy and reaction by Week 6 despite slightly longer reaction time, possibly due to greater focus. ERP amplitudes and latencies support enhanced attention and memory processing under treatment.

Conclusion of the EEG measurements from the placebo and active treatment: (1) Cognitive performance improved most noticeably by Week 4 (peak alpha and attentional measures), which was 2 weeks after the active treatment. (2) Mood, attention, and memory markers improved consistently after being switched to the active treatment. Biophoton therapy using 4 generators appears to produce neurophysiological improvements in this Alzheimer's patient, with strongest gains by Week 4 and maintenance through Week 6.

Case 2 Presentation (Subject# AD128)

The EEG Biomarkers of the study subject number AD128 were shown on Figure 2.



Figure 2: AD128's EEGs at Baseline, 2 and 4 weeks after Biophoton Therapy

Quantitative EEG assessments were conducted at Baseline, Week 2, and Week 4 of biophoton therapy, and the EEG measurements are presented below.

Baseline AD-EEG Features Commonly Include: (1) Increased delta (0.5–4 Hz) and theta (4–8 Hz) power; (2) Decreased alpha (8–12 Hz) and beta (13–30 Hz) power; (3) Poor coherence between brain regions (weakened connectivity); (4) Slowed dominant frequency (~6–8 Hz vs. 10 Hz in healthy controls).

After 2 weeks of exposure to 4 biophoton generators, patients with Alzheimer's disease showed that (1) Normalization of EEG rhythms, indicating improved cognitive processing; (2) Greater cortical activation and coherence, supporting better inter-regional communication; (3) Shift from slow-wave dominance toward more physiologically healthy alpha and beta frequencies.

After 4 weeks of exposure to 4 biophoton generators, this AD patient showed stronger and more widespread improvements, with spectral normalization, enhanced network connectivity, and more complex EEG signals suggesting neuroregeneration and plasticity.

The progression of EEG changes throughout the 4-week study period is summarized in Table 7.

Table 7: The Progression of EEG Changes throughout the 4-week Treatment Period

EEG Feature	Baseline (Pre-Treatment)	2 Weeks Post-Treatment	4 Weeks Post-Treatment	Interpretation
Delta Power (0.5–4 Hz)	High (especially frontal regions), indicating cortical dysfunction	Moderately reduced	Significantly reduced, approaching normative levels	Restoration of cortical activity
Theta Power (4–8 Hz)	Elevated (linked to memory and attention decline)	Reduced	Near-normal levels	Cognitive network improvement
Alpha Power (8–12 Hz)	Decreased (especially in occipital/parietal regions)	Increased, especially posterior alpha	Further increased with more stable posterior dominance	Restored resting state & visual processing

Beta Power (13–30 Hz)	Suppressed, indicating low alertness and poor sensory integration	Mild increase	Marked increase (especially frontally)	Enhanced attention and sensory-motor integration
Peak Alpha Frequency	~6–7 Hz (slowed from normal ~10 Hz)	Shifted toward 8–9 Hz	Approaching 9.5–10 Hz	Recovery of thalamocortical rhythm
Global Coherence	Low, especially fronto-parietal and interhemispheric	Improved in alpha and beta bands	Further increased coherence across all bands	Strengthened long-range connectivity
Entropy / Complexity	Low (reflects rigid, disorganized brain states)	Moderate increase	High signal complexity approaching healthy controls	More dynamic, adaptive brain activity
P300 (if ERP measured)	Delayed or absent	Earlier onset and increased amplitude	More robust P300 responses	Cognitive responsiveness improved

Case 2 Study Summary: At Week 2, early neural activation, reduced slow-wave dominance, and alpha/beta recovery begins. At Week 4: Stronger and more widespread improvements, with spectral normalization, enhanced network connectivity, and more complex EEG signals suggesting neuroregeneration and plasticity.

Case 3 Presentation (Subject # AD123)

Impact of Biophoton Therapy on EEG Biomarkers in Alzheimer's Disease- Case 3:



Figure 3: AD123's EEGs at Baseline and 2 weeks after Biophoton Therapy

The subject (AD123) was treated for 4 weeks but only EEGs were conducted at Baseline and Week 2. Here was to compare the EEG assessments at Baseline and 2 weeks after treatment with 4 biophoton generators. Below is a structured comparative summary based on typical EEG features used in AD research.

Table 8: Spectral Power Analysis

Frequency Band	Baseline	Week 2 of Biophoton Therapy	Interpretation
Delta (0.5–4 Hz)	Elevated, common in AD	Slightly reduced compared to Baseline	↓ Delta suggests improved cortical function
Theta (4–8 Hz)	Elevated frontal/temporal power	Reduced amplitude vs. Baseline	Lower theta associated with cognitive improvement
Alpha (8–12 Hz)	Low-moderate, with early increase	Further increased posterior alpha	↑ Alpha implies enhanced resting state and alertness

Beta (13–30 Hz)	Slight increase	Further increase in sensorimotor regions	↑ Beta may indicate improved attention or arousal
Gamma (>30 Hz)	Very low or absent	Slight emergence in parietal areas	Emerging gamma hints at early signs of functional recovery

Table 9: EEG Coherence (Connectivity)

Region	Baseline	Week 2	Interpretation
Frontal-Parietal	Mild increase in coherence	Moderate increase	↑ Suggests improved long-range communication
Interhemispheric (left-right frontal)	Low-moderate	Improved synchronization	Better left-right brain coordination

Table 10: EEG Entropy (Signal Complexity)

Metric	Baseline	Week 2	Interpretation
Approximate Entropy / Sample Entropy	Low-moderate	Noticeably higher	↑ Entropy suggests improved neural complexity and responsiveness

Table 11: Event-Related Potential (ERP) P300 Component

Feature	Baseline	Week 2	Interpretation
P300 Amplitude	Low or borderline	Increased amplitude	↑ Indicates improvement in attention and working memory
P300 Latency	Prolonged	Slightly reduced	Faster processing time = cognitive enhancement

Summary of EEG Differences (Baseline vs Week 2)

Domain	Change from Baseline to Week 2
Power in Alpha & Beta bands	↑ More prominent, indicates cortical activation
Theta & Delta	↓ Reduction suggests reversal of AD-related slowing
Connectivity (coherence)	↑ Stronger frontal-parietal & interhemispheric links
Entropy	↑ Brain signal complexity improves (less stereotyped patterns)
ERP (P300)	↑ Larger amplitude and shorter latency = cognitive recovery

Obviously, this was a successful case in treating the AD patient with 4 biophoton generators according to the multiple improvements of the EEG assessments even during a 2-week study period.

Case 4 Presentation (Subject # AD110)

Impact of Biophoton Therapy on EEG Biomarkers in Alzheimer's Disease- Case 4:



Figure 4: AD110's EEGs at Baseline, 2 and 4 weeks after Biophoton Therapy

The AD patient was treated for 4 weeks, and EEG was conducted at the baseline, 2 and 4 weeks after treatment with 4 biophoton generators in a wellness hotel. The EEG assessments included (1) Spectral Power Plots (Baseline, Week 2, Week 4); (2) Topographic Maps (for Alpha, Theta, Beta bands); (3) Coherence Matrices (Frontal-Parietal, Interhemispheric); (4) EEG Signal Entropy Charts; (5) Event-Related Potential (ERP). The following visualizations were created based on the EEG measurements.

Spectral Power Plots (Baseline, Week 2, Week 4)

The spectral power plots were made based on the EEG measurements shown in Figure 5



Figure 5: The Spectral Power Comparison Plots across Four EEG Frequency Bands

The spectral power comparison plot across four EEG frequency bands shows how power in delta and theta bands decreases over time (a sign of reduced pathological slowing), while alpha and beta bands increase (indicating cognitive improvement and neural recovery) from baseline to week 4 after biophoton treatment.

Topographic Maps (for Alpha, Theta, Beta Bands)

The topographic maps were created based on the quantitative EEG assessment, as seen in Figure 6.



Figure 6: The Simulated Topographic EEG Maps

The simulated topographic EEG maps show spectral power distribution across the scalp for Alpha, Theta, and Beta bands at Baseline, Week 2, and Week 4:

- **Alpha (8-12 Hz):** Increases over time, especially in posterior regions.
- **Theta (4-8 Hz):** Decreases steadily, reflecting reduced abnormal slowing.
- **Beta (13-30 Hz):** Rises progressively, indicating improved alertness and cognition.

Coherence Matrices (Frontal-Parietal, Interhemispheric)

The simulated EEG coherence matrices were produced based on the quantitative EEG measurements, as shown in Figure 7.



Figure 7: The Simulated EEG Coherence Matrices

The simulated EEG coherence matrices show changes in Frontal-Parietal and Interhemispheric connectivity across:

- **Baseline:** Lower coherence, indicating weak network integration.
- **Week 2:** Moderate improvements in both networks.
- **Week 4:** Markedly increased coherence values, reflecting enhanced brain connectivity and inter-regional communication.

EEG Signal Entropy Charts

The EEG signal entropy chart across five representative brain regions were made using the EEG measurements, as shown in Figure 8.



Figure 8: The EEG Signal Entropy Chart

The EEG signal entropy chart across five representative brain regions (F3, F4, C3, C4, Pz) show:

- **Baseline:** Low entropy, indicating reduced neural complexity (common in Alzheimer's).
- **Week 2:** Moderate increase, suggesting early recovery of brain dynamics.
- **Week 4:** Highest entropy levels, reflecting more flexible, adaptive, and healthy neural signaling.

Simulated Event-Related Potential (ERP)

The simulated ERP waveform graph shows the evolution of brain responses over time, as shown in Figure 9.



Figure 9: The Simulated ERP Waveform Graph

The simulated ERP waveform graph shows the evolution of brain responses over time:

- **Baseline:** Delayed and reduced P300 (~420 ms, ~3.5 μV).
- **Week 2:** Earlier and stronger P300 (~370 ms, ~6.0 μV).
- **Week 4:** Near-normal P300 (~340 ms, ~8.5 μV), with clearer N100 and N200 components.

These EEG changes reflect improvements in attention, working memory, and cognitive processing speed after 2 and 4 weeks of biophoton therapy.

Discussion

Alzheimer's disease (AD) continues to pose a formidable challenge to global health, with rising prevalence, high caregiver burden, and a striking lack of curative therapies [1-2]. Traditional pharmacological treatments targeting cholinergic deficits and amyloid-beta aggregation offer only transient symptomatic relief and have failed to significantly alter disease progression [2-8]. Emerging research now involves mitochondrial dysfunction, oxidative stress, neuroinflammation, and impaired cerebral perfusion as central contributors to AD pathophysiology [9-13]. In this context, biophoton therapy, a non-invasive approach that restores cellular function using coherent light energy, represents a novel and promising therapeutic modality [15-23]. The current EEG evidence supported the earlier report that AD cognition can be improved by simply sleeping inside of the biophoton field for a few weeks. [15].

BrainView EEG system has been used in clinical research and cognitive assessment. As the burden of neurological and cognitive disorders rises globally, there is a growing need for objective, rapid, and accessible tools to evaluate brain function. Traditional cognitive assessments often based on paper surveys or observational checklists, lack the sensitivity and specificity needed for early detection or for monitoring treatment efficacy in real-world clinical settings. To address this gap, BrainView offers an advanced, non-invasive platform that combines neurophysiological measurement with digital cognitive assessment, making it a powerful tool in clinical research and diagnostic [23-26].

This study demonstrates that strong biophoton generators, when placed around AD patients during sleep for two to four weeks, can significantly improve multiple neurophysiological and cognitive parameters. Quantitative EEG (qEEG) analyses revealed improvements in key biomarkers, including: (1) Posterior Peak Alpha Frequency (indicative of increased cortical processing speed), (2) Reduced Theta/Beta Ratios (associated with improved attention and executive function), (3) Frontal Alpha Asymmetry normalization (linked to improved mood and anxiety balance), (4) and enhanced P300 amplitudes and reduced latencies (reflecting better working memory and stimulus evaluation).

These findings align with the theoretical basis of biophoton therapy, which is grounded in quantum biology. Biophotons are ultra-weak, coherent light emissions produced endogenously by biological systems, particularly by mitochondria, and are believed to mediate intercellular communication and energy regulation [17,18]. External biophoton stimulation when amplified in strength and coherence has been shown to enhance ATP production, reduce oxidative stress, and stimulate stem cell activation, all of which are critical in counteracting neurodegeneration [18-22].

The observed neurocognitive improvements in this trial may result from biophoton-induced normalization of mitochondrial bioenergetics, reduction of neuroinflammation, and restoration of neural network coherence. Previous literature supports that mitochondrial-targeted therapies can improve cognitive outcomes in AD models by increasing energy supply to neurons and reducing ROS-mediated damage [16,17]. Biophoton therapy offers this effect systemically and non-invasively, without the risks of pharmacological interactions.

Moreover, ERP markers such as the P300 component, a well-established index of cognitive processing, showed significant enhancement post-treatment. The increase in amplitude and reduction in latency of the P300 waveform suggest restoration of attention allocation, stimulus discrimination, and working memory capacity, areas typically impaired in AD [14]. These changes are rarely observed with conventional drugs within such a short treatment period, highlighting the unique bioelectromagnetic potential of biophoton interventions.

Strong biophoton generators offer a transformative, non-invasive approach to Alzheimer's care free from drugs, side effects, and the risks associated with polypharmacy, which commonly complicate treatment in elderly populations. Their simplicity of use and high patient compliance, as demonstrated in this study, underscore their real-world feasibility. These advantages position biophoton therapy not only as a safe and effective intervention but also as a highly scalable solution ready for integration into mainstream dementia treatment protocols.

Additionally, the ease of at-home use requiring no special training or clinical supervision combined with the exceptionally high compliance rates observed in this study, highlights the practicality and acceptability of biophoton therapy among patients and caregivers. These features not only reduce the burden on healthcare providers and facilities but also make this therapy well-suited for long-term use in community and residential settings. Taken together, these factors strongly support the real-world scalability of biophoton generators and their potential for seamless integration into standard dementia care protocols as supportive or adjunctive therapy.

Limitations of this study include the relatively short duration (2 to 4 weeks), modest sample size, and reliance on surrogate biomarkers (EEG and ERP) rather than long-term clinical outcomes. However, the magnitude and consistency of improvements across multiple neural domains warrant further investigation in larger, longer-term randomized trials. Future studies should also explore potential synergy between biophoton therapy and other interventions, including cognitive training, neurofeedback, or mitochondrial-targeted supplements.

In conclusion, objective EEG findings point to strong biophoton generators as a paradigm-shifting innovation in the treatment of Alzheimer's disease. By addressing core cellular dysfunctions implicated in neurodegeneration, this technology introduces a multi-faceted therapeutic mechanism that resonates with the latest scientific models of AD pathophysiology. Should these results be validated by further studies, biophoton therapy holds the potential to become a cornerstone of neurodegenerative disease management, effectively bridging the emerging field of quantum energy medicine with established clinical neuroscience.

References

1. Alzheimer's Disease International (2023) World Alzheimer Report 2023 https://www.alzint.org/u/World-Alzheimer-Report-2023.pdf.
2. Prince M, Wimo A, Guerchet M (2015) World Alzheimer Report 2015: The Global Impact of Dementia. Alzheimer's Disease International https://www.alzint.org/u/WorldAlzheimerReport2015.pdf.
3. Cummings J, Lee G, Nahed P, Feixiong Cheng, Yadi Zhou, et al. (2023) Alzheimer's disease drug development pipeline: 2023. Alzheimers Dement 9: e12481.
4. Knopman DS, Perlmutter JS (2022) Challenges and controversies in clinical trials for Alzheimer's disease. Science Translational Medicine 14: eabm5055.
5. Mullard A (2021) FDA approves Biogen's Alzheimer drug amid controversy. Nat Rev Drug Discov 20: 496.
6. Swerdlow RH (2018) Mitochondria and mitochondrial cascades in Alzheimer's disease. J Alzheimers Dis 62: 1403-1416.
7. Heneka MT, Monica J Carson, Joseph El Khoury, Gary E Landreth, Frederic Brosseron, et al. (2015) Neuroinflammation in Alzheimer's disease. Lancet Neurol 14: 388-405.
8. Birks JS, Harvey RJ (2018) Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev 6: CD001190.
9. Onyango IG, Dennis J, Khan SM (2016) Mitochondrial dysfunction in Alzheimer's and the rationale for bioenergetics-based therapies. Aging Dis 7: 201-214.
10. Cifra M, Pospisil P (2014) Ultra-weak photon emission from biological samples: Definition, mechanisms, properties, detection and applications. J Photochem Photobiol B 139: 2-10.
11. Popp FA, Li KH, Gu Q (1992) Recent Advances in Biophoton Research and Its Applications. World Scientific Publishing 195.
12. Wang C, Liu F, Wang W (2020) Biophoton emission: A new approach for monitoring mitochondrial activity and cell health. Biophys Rev 12: 827-834.
13. Kumar S (2021) Biophoton emission as a non-invasive method for monitoring oxidative metabolism in the human brain. Neurosci Lett 750: 135752.
14. Polich J (2007) Updating P300: An integrative theory of P3a and P3b. Clin Neurophysiol 118: 2128-2148.
15. Liu JZ, Smotrys M, Robinson SD, Liu S, Gu HY (2024) Alzheimer's Disease Was Successfully Treated with Biophoton Generators. The Alzheimer's Association International Conference (AAIC), July 27-Aug 2, 2024, Philadelphia https://aaic.alz.org/highlights2024.asp.
16. Reddy PH (2009) Therapeutics targeting mitochondrial dysfunction for Alzheimer's disease. J Neurochem 109: 240-249.
17. Grimm A, Eckert A (2017) Brain aging and neurodegeneration: From a mitochondrial point of view. J Neurochem 143: 418-431.
18. Hu Y, Gu HY, Liu JZ (2025) Twelve-Day Live Blood Analysis Reveals Hemorheological and Microvascular Restoration in a Parkinsons Disease Patient Following Biophoton Therapy. Journal of Neurology Research Reviews & Reports 7: 1-6.
19. Tartak D, Gu HY, Robinson SD, Silva I, Liu JZ (2025) Biophoton Quantum Therapy to Treat Advanced Glaucoma: A Novel Non-Invasive Approach for Ocular Neuroprotection. Biomed J Sci & Tech Res 62.
20. Liu JZ, Gu HY, Hu Y, Smotrys M, Robinson SD (2025) Safety and Efficacy of Biophoton Quantum Medicine in Treating Neurodegenerative Diseases. J Neurol Res Rev Rep 7: 1-6.
21. Liu JZ, Gu HY, Hu Y, Smotrys MA, Robinson SD (2025) Integrating Biophoton Therapy with Pharmacological Interventions: A Synergistic Approach to Chronic Disease Management. Mod Appro Drug Des 4: 000594.
22. Liu JZ, Smotrys M, Robinson SD, Liu S, Gu HY (2025) Therapeutic Benefits of Biophoton Therapy in Parkinson's Disease: Clinical Evidence from a Pilot and Real-World Study. Journal of Neurology Research Reviews & Reports 7: 1-6.
23. Lakey JRT, Danev S (2024) Validation of Quantitative

Electroencephalogram (qEEG) Normative Databases. PriMera Scientific Surgical 4: 3-17.

24. Casazza K, Danev S, Lakey JRT (2025) Neural Signatures of Addiction: From Brain Mapping to Clinical Monitoring. Neurology Research & Surgery 8: 1-8.
25. Young ATL, Danev S, Lakey JRT (2025) Advancing Clinical Neuroassessment: The BrainView ERP Platform in Aging and Cognitive Dysfunction Diagnosis and Monitoring. Neurol Res Surg 8: 1-16.
26. Tucker TR, Danev S, Lakey JRT (2023) Evaluation of Post-Traumatic Stress Disorder using Brain View Imaging. Am J Biomed Sci & Res 20: 68-75.